Treatment of *C. difficile* infections by anti-sporulation activity, resulting in a reduction in the rates of reinfection. Monash researchers have identified off-patent compounds that inhibit *C. difficile* sporulation offering improved, cost-effective outcomes for patients when used in combination with the existing first-in-line treatment.

- **Demonstrated anti-sporulation activity**
- **Anticipated combination therapy using off-patent drugs**

### THE CHALLENGE

*Clostridium difficile* is a spore-forming bacterium and the leading cause of antibiotic-associated nosocomial diarrhoea worldwide. It results in 250,000 infections and 14,000 deaths each year in the US, at an estimated medical cost of US$1 billion (US Centers for Disease Control and Prevention - CDC)¹.

Patient susceptibility to *C. difficile* results from antibiotic treatment for an unrelated condition. Disruption of the natural gut microbiota allows this bacterium to colonise and flourish².

Antibiotics are used to treat most *C. difficile* cases, but are not very effective at managing recurrent or severe disease and there are no vaccines available. There is therefore an urgent need to develop alternative therapies targeting this bacterium².

*C. difficile* produces spores which are generated in large numbers in the host gut. The Lyras laboratory at Monash University has shown that *C. difficile* spores play a very important role in virulence, causing disease recurrence and increasing disease severity (unpublished data).

Strategies preventing or reducing spore production from *C. difficile* would be invaluable for infection control and disease reduction purposes; however, none are available.

To date, there are no reported molecular targets for the inhibition of sporulation in *C. difficile* nor have any specific inhibitors of sporulation been identified.

### THE TECHNOLOGY

Researchers in the Lyras laboratory have developed novel sporulation blocking strategies by repurposing old drugs. We have identified off-patent compounds that inhibit current virulent forms of *C. difficile* sporulation; no such compounds are available for any spore-forming bacteria.

*In vitro* studies demonstrate significant decreases in spore survival relative to untreated cells; *in vivo*, using our mouse infection model (3), results are highly significant, with a 13-40 fold reduction seen in rates of sporulation when using the generic compounds identified in the Lyras laboratory (Fig. 1).

We have also identified the molecule targets for these compounds and we are currently performing genetic and biochemical DNA structural studies with them. Expected outcomes are:

- Combination therapy with current standard-of-care
- Reduction in recurrence, transmission and disease severity (a formal validation is in progress).

**Intellectual property:** Provisional patent application – in draft.

### THE OPPORTUNITY

We seek a partner to support the commercialization of a novel drug combination using current generic drugs, for the treatment of virulent forms of *C. difficile* that result in lower rates of reinfection than is currently achievable.

### References


### CONTACT US

Dr John Morrison  
Director, Research Translation  
Monash Medicine, Nursing & Health Sciences  
T: +61 3 9902 0183  
E: john.morrison@monash.edu